Our patented production method was originally invented in Aalto University and now Nordic Bioproducts Group is the sole owner of the AaltoCell™ patent portfolio.
Currently the rights to sell and produce our technology has been outlicensed globally to our partner Andritz Oy, the world leading pulp and paper technology provider.
AaltoCell™ biotechnology produces in a large industrial scale Micro Crystalline Cellulose (MCC) and new high-value-adding biocomponents from a wide variety of cellulose containing materials.
Our technology is fully ready for implementation, offering a fast-track to markets with sustainable technology and bioproducts.
The Aaltocell process is highly flexible, enabling the use of a wide variety of feedstock ranging from plant-based sidestreams and residues to paper-grade pulp. The size and properties of the produced microcrystalline cellulose (MCC) can be tuned for the requirement of different end-use applications.
Enabling high-value cellulose derivatives